Business Wire

EKF Life Sciences and ABEC Partner for US Biomanufacturing Expansion

Share

ABEC, a leading global provider of engineered solutions and services for biotech manufacturing, today announced it will provide customized, large-scale bioprocess equipment, including a 14,500 liter total volume stainless steel fermenter and an 8,000 liter media preparation system to EKF Life Sciences, a division of EKF Diagnostics Holdings plc, which manufactures diagnostics enzymes and contracted custom products for use in medical diagnostics, pharmaceutical and industry. The agreement provides EKF Life Sciences’ South Bend, Indiana facility with the bioprocess equipment which will significantly expand EKF’s production capacity of enzymes used in a variety of diagnostic and Life Science applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220308005235/en/

An industry leader in high-quality diagnostic materials, EKF is committed to the timely and cost-effective supply of critical products to the global life science and healthcare industries. ABEC has over 45 years of experience in large-scale fermenter design and complete in-house engineering and manufacturing capabilities. ABEC will provide engineering services for EKF’s new fermentation facility to ensure optimal process performance and seamless facility integration. The 14,500 liter fermenter will feature ABEC’s patented internal cooling panels, which will enable efficient sanitation, optimal heat removal and the highest possible fermenter productivity.

“EKF Life Sciences is dedicated to developing new products and capabilities that best serve the in vitro diagnostic market on a global scale. The partnership with ABEC is another important step in accelerating our organic growth strategy,” said Mike Salter, CEO of EKF Diagnostics Holdings plc. “Their innovative equipment and resources will enable us to quickly deliver our specific manufacturing requirements and we look forward to working with them as we continue to expand our biomanufacturing capabilities and capacity.”

“ABEC’s innovative technologies and complete turnkey solutions are unique in the industry,” said Scott Pickering, ABEC CEO and Chairman. “We look forward to continuing to support EKF’s expansion and growth.”

About ABEC

Since 1974, ABEC has been a global leader in delivering engineered process solutions and services for manufacturing in the biotech industry. A majority of the world's pharmaceutical and biotech companies are ABEC customers; with many of today's leading therapies manufactured by processes and equipment engineered, manufactured, installed and serviced by ABEC. ABEC's unique value is based on long experience, complete in-house capabilities, a custom, flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities, ABEC's turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. Visit: abec.com, email info@abec.com.

About EKF Life Sciences

EKF Life Sciences has been manufacturing enzymes and related biomolecules from bacterial fermentation for use in IVD since 1983. Since then, it has developed core competencies in technology transfer to commercialization, and the scale up of fermentation processes from bench top vessels to manufacturing large scale stable and reliable enzymes. These enzymes can be consistently produced in bulk scale for mass production of test kits.

With the continued development of microbial expression platforms and the expanding interest in medical and industrial applications for biologically produced intermediates and products, EKF Life Sciences serves as a critical link in the evolution of improved and environmentally sensitive manufacturing processes.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Susan Cooper Curcio, +1 (610) 861 4666scurcio@abec.com

Walbrook PR Limited
Paul McManus / Lianne Applegarth
Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Starr Insurance Companies Expands in Thailand17.5.2022 22:33:00 CEST | Press release

Starr Insurance Companies (Starr) announced an agreement with FPG Insurance Holdings Limited (HK) (FPG) and local Thai shareholders to purchase FPG Insurance Public Company Limited (FPG Thailand), a Thai non-life insurance company, together with local Thai parties. Starr’s investment will be held by its Bermuda insurance company, Starr Insurance & Reinsurance Limited. The transaction is expected to close in the second quarter of 2022, subject to certain customary closing conditions, including any necessary regulatory approvals. “Thailand is an important, fast-growing insurance market — one of the cornerstones of the Southeast Asia economy,” said Maurice R. Greenberg, Starr’s Chairman & CEO. “Asia is both commercially and culturally important to Starr, as we trace our roots to an American-owned company founded in Shanghai more than 100 years ago. We look forward to serving the needs of local Thai companies and consumers through this new insurance capability.” David Zuellig, FPG regional

Emendo Biotherapeutics’ next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE -related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting17.5.2022 22:15:00 CEST | Press release

Emendo Biotherapeutics presented the results of its next generation CRISPR-based gene editing approaches for several indications in an oral presentation and three posters at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held May 16-19, 2022, in Washington, D.C. Emendo presented pre-clinical data for the treatment of ELANE-related Severe Congenital Neutropenia using an allele-specific editing approach, demonstrating the power of Emendo’s dual technology platforms that enable the development of a highly specific editing composition that demonstrates no off-targets and complete allele specificity. Significantly, the lack of off-target achieved by Emendo’s engineered and optimized OMNI nuclease also eliminated any translocations. Edited patient derived CD34+ cells differentiated normally into neutrophils both in-vitro and in-vivo, showing full engraftment and reconstitution of all blood lineages, as required for the desired therapeutic effect. “ELANE-based

Piper Sandler Advises PETRONAS Chemicals Group Berhad on Acquisition of Perstorp17.5.2022 19:59:00 CEST | Press release

Piper Sandler & Co. chemicals investment banking announced today that it has advised PETRONAS Chemicals Group Berhad (PCG) on its acquisition of Perstorp Holding AB. The transaction Enterprise Value is €2,300 million and base purchase price, less adjusted net debt, is €1,538 million. It is expected to close in Q3 2022 subject to customary closing conditions. PCG is the leading integrated chemicals producer in Malaysia and one of the largest in Southeast Asia. It operates a number of world-class production sites, which are fully vertically integrated from feedstock to downstream end-products. With a total combined production capacity of 12.8 million metric tons per annum (mtpa), it is involved primarily in manufacturing, marketing, and selling a diversified range of chemical products, including olefins, polymers, fertilizers, methanol and other basic chemicals and derivative products. Listed on Bursa Malaysia in 2010 and with more than three decades of experience in the chemicals indust

Morinaga Milk Obtains the Registration of "New Food Ingredient" in China for Use of Its Probiotic Bifidobacterium longum BB536 in Infant and Toddler Foods17.5.2022 19:53:00 CEST | Press release

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium longum BB536 was approved by the National Health Commission (NHC) of the People’s Republic of China as a new food ingredient for use in infant and toddler foods (under the age of three) on 11th May 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005112/en/ Morinaga Milk obtains the registration of "New Food Ingredient" in China for use of its probiotic Bifidobacterium longum BB536 in infant and toddler foods on 11th May 2022. (Graphic: Business Wire) Following a complex and lengthy registration process, the probiotic strain B. longum BB536 meets the highest standards of safety and regulatory compliance and has now completed the approval process for use as an ingredient in infant and toddler milk and food products for children under three years old in China. “We are extr

Hiro Capital Joins Knollwood and Boost VC With Major Investment in Skybound Entertainment17.5.2022 19:30:00 CEST | Press release

Hiro Capital has invested in Skybound Entertainment in a significant, undisclosed round led by Knollwood Advisory with participation from Boost VC, and follow-on participation from Com2uS and Skydance Entertainment. Skybound Entertainment is home to acclaimed franchises including The Walking Dead, Invincible, and Impact Winter. “There is nothing more powerful than storytelling, and I’m delighted that Hiro has been able to invest in Skybound Entertainment, creators and curators of extremely compelling omniverses,” said Sir Ian Livingstone, Co-Founding Partner of Hiro Capital. “Hiro’s trust in our vision will help us accelerate the evolution of existing hit franchises as well as new content for our fan base around the world,” said Skybound CEO David Alpert. Skybound brings together creators across its multi-faceted business, including comics, interactive games, audio, film, and television (traditional and digital platforms), licensing, and merchandising. Skybound has successfully franchi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom